GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus
Updated: December 13, 2025 GSK plc (LSE: GSK, NYSE: GSK) is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3 As of the latest available quote, GSK’s U.S.-listed ADR was about $48.81, with